SG183114A1 - Cancer diagnosis and imaging - Google Patents
Cancer diagnosis and imaging Download PDFInfo
- Publication number
- SG183114A1 SG183114A1 SG2012055232A SG2012055232A SG183114A1 SG 183114 A1 SG183114 A1 SG 183114A1 SG 2012055232 A SG2012055232 A SG 2012055232A SG 2012055232 A SG2012055232 A SG 2012055232A SG 183114 A1 SG183114 A1 SG 183114A1
- Authority
- SG
- Singapore
- Prior art keywords
- cell cycle
- imaging
- cycle inhibitor
- mammal
- condition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30903010P | 2010-03-01 | 2010-03-01 | |
| PCT/US2011/026416 WO2011109262A2 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG183114A1 true SG183114A1 (en) | 2012-09-27 |
Family
ID=44542787
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012055232A SG183114A1 (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
| SG10201501496TA SG10201501496TA (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201501496TA SG10201501496TA (en) | 2010-03-01 | 2011-02-28 | Cancer diagnosis and imaging |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9427429B2 (https=) |
| EP (1) | EP2542155B1 (https=) |
| JP (1) | JP6017964B2 (https=) |
| KR (1) | KR101821343B1 (https=) |
| CN (1) | CN102781316B (https=) |
| AU (1) | AU2011223883B2 (https=) |
| CA (1) | CA2787673A1 (https=) |
| ES (1) | ES2557407T3 (https=) |
| IL (1) | IL221035A0 (https=) |
| MX (1) | MX360640B (https=) |
| SG (2) | SG183114A1 (https=) |
| WO (1) | WO2011109262A2 (https=) |
| ZA (1) | ZA201205377B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9212127B2 (en) * | 2004-08-20 | 2015-12-15 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| EP2542155B1 (en) | 2010-03-01 | 2015-11-04 | TAU Therapeutics LLC | Method for imaging a disease |
| EP3487516A1 (en) * | 2016-07-19 | 2019-05-29 | Bristol-Myers Squibb Company | Radioligands for imaging the ido1 enzyme |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219609A (en) | 1968-07-19 | 1971-01-20 | Koninklijke Pharma Fab Nv | Diphenylmethoxyethylamino derivatives |
| US3732247A (en) | 1970-08-14 | 1973-05-08 | Robins Co Inc A H | 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms |
| US4091103A (en) | 1976-06-23 | 1978-05-23 | Ciba-Geigy Corporation | Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives |
| JPS59161392A (ja) | 1983-03-04 | 1984-09-12 | Nippon Shinyaku Co Ltd | ジヒドロピリジン誘導体及びその製法 |
| US4906646A (en) | 1983-03-31 | 1990-03-06 | Board Of Governors Of Wayne State University | Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class |
| US4885284A (en) | 1986-01-22 | 1989-12-05 | Nissan Chemical Industries Ltd. | Dihydropyridine-5-phosphonic acid cyclic propylene ester |
| FR2601366B1 (fr) | 1986-07-10 | 1988-11-25 | Andre Buzas | Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant. |
| CA1334752C (en) | 1988-08-02 | 1995-03-14 | Ryozo Sakoda | Drug effect-enhancing agent for antitumor drug |
| JP2850376B2 (ja) | 1988-08-02 | 1999-01-27 | 日産化学工業株式会社 | 抗癌剤薬効増強剤 |
| FR2636946B1 (fr) | 1988-09-23 | 1990-11-02 | Lipha | ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| EP0467435A3 (en) | 1990-07-19 | 1992-04-01 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6413967B1 (en) | 1995-03-30 | 2002-07-02 | The University Of Virginia Patents Foundation | Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy |
| EP0848614B1 (en) | 1995-09-08 | 2006-04-26 | Beth Israel Deaconess Medical Center | Isolation of microdomains of caveolae and gpi-anchored proteins |
| DE69631058T2 (de) | 1995-09-15 | 2004-06-03 | Neurosearch A/S | Piperindinverbindungen als calcium-kanal-blocker |
| NZ331217A (en) | 1996-02-14 | 2000-02-28 | Novartis Ag | Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand |
| CA2204082A1 (en) | 1996-05-03 | 1997-11-03 | Michael William John Urquhart | Pharmaceutical compounds |
| US6191156B1 (en) | 1997-04-11 | 2001-02-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating bladder dysfunction |
| US6703374B1 (en) | 1997-10-30 | 2004-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleosides for imaging and treatment applications |
| EP1042468B1 (en) | 1997-12-03 | 2006-10-18 | Merck & Co., Inc. | Low-voltage activated calcium channel compositions and methods |
| CA2312477A1 (en) | 1997-12-05 | 1999-06-17 | Loyola University Of Chicago | T-type voltage-gated calcium channels and method of using same |
| JPH11246417A (ja) | 1998-03-04 | 1999-09-14 | Nissan Chem Ind Ltd | 糖尿病性腎症治療用医薬組成物 |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| JP2002525077A (ja) * | 1998-08-26 | 2002-08-13 | サウス、アラバマ、メディカル、サイエンス、ファウンデーション | Ｔ型カルシウムチャンネル |
| US6251886B1 (en) | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
| EP1165508B1 (en) | 1999-04-07 | 2004-06-23 | The University of Virginia Patent Foundation | Anticancer calcium channel blockers |
| US6946475B1 (en) | 1999-04-07 | 2005-09-20 | University Of Virginia Patent Foundation | Anticancer calcium channel blockers |
| US7195783B2 (en) | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
| WO2001062740A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Mibefradil analogues and their use |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| AU7804501A (en) | 2000-07-27 | 2002-02-13 | Pharmacia Corp | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| KR100863624B1 (ko) | 2001-05-11 | 2008-10-15 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체 |
| AU2002328945A1 (en) | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Methods for improved treatment of cancer with irinotecan based on mrp1 |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| EP1506032A1 (en) | 2002-05-20 | 2005-02-16 | Research Development Foundation | Aerosol drug inhibition of lung metastases |
| GB0211578D0 (en) * | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| DE10227511A1 (de) | 2002-06-19 | 2004-01-08 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| CA2499599A1 (en) * | 2002-09-17 | 2004-04-01 | New York University | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
| NZ542681A (en) | 2003-03-28 | 2009-01-31 | Nissan Chemical Ind Ltd | T-type calcium channel blockers comprising optically active 1,4-dihydropyridines |
| TW200528107A (en) | 2003-11-25 | 2005-09-01 | Nissan Chemical Ind Ltd | T-type calcium channel inhibitor |
| AU2011203315B8 (en) | 2004-02-11 | 2012-02-16 | University Of Virginia Patent Foundation | Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer |
| JP2008501633A (ja) | 2004-02-11 | 2008-01-24 | ユニバーシティ オブ ヴァージニア パテント ファウンデーション | 癌の診断及び治療のためのＣａｖ３アイソフォーム及びそのδ２５スプライスバリアントの阻害 |
| US20070178462A1 (en) | 2004-02-18 | 2007-08-02 | Uebele Victor N | Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha1h, encoded proteins and methods of use thereof |
| US20060003020A1 (en) | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| WO2006003020A1 (en) | 2004-07-02 | 2006-01-12 | L'oreal | Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof |
| US20100222406A1 (en) | 2007-09-11 | 2010-09-02 | University Of Virginia Patent Foundation | T Type Calcium Channel Blockers and the Treatment of Diseases |
| US9212127B2 (en) | 2004-08-20 | 2015-12-15 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| US20120264804A1 (en) | 2004-08-20 | 2012-10-18 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| AU2005277154B2 (en) | 2004-08-20 | 2011-11-24 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| US7851431B2 (en) | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| CN101528768A (zh) * | 2006-08-10 | 2009-09-09 | 肿瘤疗法科学股份有限公司 | 与乳腺癌相关的基因和多肽 |
| JP5339291B2 (ja) * | 2006-08-10 | 2013-11-13 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
| HUE029445T2 (en) | 2006-12-19 | 2017-02-28 | Genentech Inc | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors |
| CA2684938A1 (en) | 2007-05-02 | 2008-11-13 | Tau Therapeutics Llc | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| WO2008141189A1 (en) | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
| HRP20160625T1 (hr) | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| JP5029328B2 (ja) | 2007-12-05 | 2012-09-19 | マツダ株式会社 | 自動車の前部車体構造 |
| US20110129456A1 (en) * | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| CN102112490B (zh) | 2008-07-08 | 2014-10-22 | 昂考梅德药品有限公司 | Notch1受体结合剂和其使用方法 |
| SG10201810806UA (en) | 2009-06-05 | 2019-01-30 | Cavion Inc | Interlaced method for treating cancer or a precancerous condition |
| EP2542155B1 (en) | 2010-03-01 | 2015-11-04 | TAU Therapeutics LLC | Method for imaging a disease |
| CN103957923B (zh) | 2011-09-12 | 2018-05-25 | 卡维昂公司 | 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂 |
-
2011
- 2011-02-28 EP EP11751125.3A patent/EP2542155B1/en not_active Not-in-force
- 2011-02-28 US US13/581,390 patent/US9427429B2/en not_active Expired - Fee Related
- 2011-02-28 SG SG2012055232A patent/SG183114A1/en unknown
- 2011-02-28 KR KR1020127022975A patent/KR101821343B1/ko not_active Expired - Fee Related
- 2011-02-28 SG SG10201501496TA patent/SG10201501496TA/en unknown
- 2011-02-28 ES ES11751125.3T patent/ES2557407T3/es active Active
- 2011-02-28 AU AU2011223883A patent/AU2011223883B2/en not_active Ceased
- 2011-02-28 JP JP2012556123A patent/JP6017964B2/ja not_active Expired - Fee Related
- 2011-02-28 CA CA2787673A patent/CA2787673A1/en not_active Abandoned
- 2011-02-28 MX MX2012010119A patent/MX360640B/es active IP Right Grant
- 2011-02-28 CN CN201180011495.2A patent/CN102781316B/zh not_active Expired - Fee Related
- 2011-02-28 WO PCT/US2011/026416 patent/WO2011109262A2/en not_active Ceased
-
2012
- 2012-07-18 ZA ZA2012/05377A patent/ZA201205377B/en unknown
- 2012-07-19 IL IL221035A patent/IL221035A0/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011223883B2 (en) | 2015-10-08 |
| EP2542155A2 (en) | 2013-01-09 |
| ZA201205377B (en) | 2013-09-25 |
| US9427429B2 (en) | 2016-08-30 |
| SG10201501496TA (en) | 2015-04-29 |
| MX360640B (es) | 2018-11-09 |
| JP6017964B2 (ja) | 2016-11-02 |
| JP2013521287A (ja) | 2013-06-10 |
| KR20130014506A (ko) | 2013-02-07 |
| EP2542155B1 (en) | 2015-11-04 |
| IL221035A0 (en) | 2012-09-24 |
| WO2011109262A3 (en) | 2011-11-17 |
| AU2011223883A1 (en) | 2012-09-13 |
| ES2557407T3 (es) | 2016-01-25 |
| CA2787673A1 (en) | 2011-09-09 |
| US20120321561A1 (en) | 2012-12-20 |
| WO2011109262A2 (en) | 2011-09-09 |
| CN102781316B (zh) | 2016-07-06 |
| EP2542155A4 (en) | 2013-07-17 |
| MX2012010119A (es) | 2012-09-12 |
| HK1179143A1 (zh) | 2013-09-27 |
| KR101821343B1 (ko) | 2018-01-23 |
| CN102781316A (zh) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9427429B2 (en) | Cancer diagnosis and imaging | |
| Geenen et al. | Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu] Lu-DOTA-TATE for the treatment of neuroendocrine tumours | |
| McDougall et al. | Thyroid stunning: fact or fiction? | |
| Schoenberger et al. | In vivo [18F] GE-179 brain signal does not show NMDA-specific modulation with drug challenges in rodents and nonhuman primates | |
| KR20210095620A (ko) | 암 치료 방법 | |
| KR20240116780A (ko) | 방사성제약 치료 방법 및 용도 | |
| Gomez-Lado et al. | [18F]-FMISO PET/MRI imaging shows ischemic tissue around hematoma in intracerebral hemorrhage | |
| US8633165B2 (en) | Neuroprotective effects of 2DG in traumatic brain injury | |
| Chang et al. | Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma | |
| HK1179143B (en) | Method for imaging a disease | |
| Pérez-Medina et al. | Synthesis and evaluation of a 125I-labeled iminodihydroquinoline-derived tracer for imaging of voltage-gated sodium channels | |
| Adams et al. | Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance | |
| IL302964A (en) | Radiolabeled liposomes and methods of use thereof | |
| KR102369838B1 (ko) | 퀴놀린 유도체를 유효성분으로 포함하는 성상교세포증 관련 질환의 병변 경계부 검출용 조영제 조성물 | |
| LUKAS | 3| GLIOBLASTOMA | |
| Ozkan et al. | Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine | |
| Zhao et al. | Intracranial 131I-chTNT brachytherapy in patients with deep-seated glioma: a single-center experience with 10-year follow-up from china | |
| KR102369854B1 (ko) | C11-아세테이트를 유효성분으로 포함하는 성상교세포증 관련 질환의 병변 경계부 검출용 조영제 조성물 | |
| Waitz et al. | Treatment of high-grade glioma with radiolabeled peptides | |
| AU2006316781B2 (en) | Therapy of malignant neoplasias | |
| US20250387523A1 (en) | Combination therapy of radionuclide complex | |
| Wadsworth | Oxygenation and radiosensitization consequences of solid tumour perfusion | |
| KR20210128125A (ko) | 퀴놀린 유도체를 유효성분으로 포함하는 퇴행성 뇌질환에 의한 치매의 병변 경계부 검출용 조영제 조성물 | |
| KR20260014588A (ko) | 전립선암의 진단 및/또는 치료 방법 | |
| Reynolds et al. | Lucia Martiniova1, 7*, Shiromi M Perera1*, Frederieke M Brouwers1, Salvatore Alesci2, Mones Abu-Asab3, Amanda F Marvelle, Dale O Kiesewetter4, David Thomasson5, John C Morris6, Richard Kvetnansky7, Arthur S Tischler8 |